New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
04:55 EDTMRGE, MRGE, KND, KND, IMMU, IMMU, COO, COO, CVS, CVS, ARNA, ARNA, GMED, GMED, ISIS, ISIS, Q, Q, STML, STML, BDSI, BDSI, DEPO, DEPOWells Fargo to hold a conference
2014 Healthcare Conference to be held in Boston on June 17-18.
News For MRGE;BDSI;STML;Q;ISIS;GMED;ARNA;CVS;COO;IMMU;KND;DEPO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 26, 2014
07:22 EDTMRGEMerge Healthcare partners with Primordial Design for radiology solutions
Subscribe for More Information
November 25, 2014
09:39 EDTARNAActive equity options trading
Subscribe for More Information
08:06 EDTARNAArena Pharmaceuticals granted patent covering ralinepag
Arena Pharmaceuticals announced that the US Patent and Trademark Office granted Arena U.S. Patent No. 8,895,776, entitled "Modulators of the Prostacyclin Receptor Useful for the Treatment of Disorders Related Thereto," covering ralinepag, an orally available agonist of the prostacyclin, or IP, receptor. Ralinepag is an investigational drug candidate being developed by Arena for the treatment of vasospastic diseases such as pulmonary arterial hypertension.
07:09 EDTISISIsis Pharmaceuticals initiates pivotal Phase 3 study evaluating ISIS-SMN
Subscribe for More Information
November 24, 2014
10:24 EDTIMMUHigh option volume stocks
High option volume stocks: TIVO TIF ASHR OCR TGP JEC CEQP UTX PWRD IMMU
November 21, 2014
14:51 EDTBDSIBioDelivery Sciences management to meet with William Blair
Subscribe for More Information
08:35 EDTIMMUImmunomedics granted FDA orphan drug designation for veltuzumab
Immunomedics announced that the Office of Orphan Products Development of the FDA has granted orphan status for the use of veltuzumab, the company's humanized anti-CD20 antibody, for the treatment of pemphigus. Pemphigus is a debilitating and potentially fatal autoimmune blistering disease of the skin and mucous membranes. In most cases, irregularly-shaped, painful erosions or lesions initially develop in the mucous membranes lining the inside of the mouth. To maintain disease control typically requires long-term exposure to corticosteroids and other drugs which suppress the immune system and may themselves contribute to osteoporosis, septicemia, and other serious adverse events seen in this population.
November 20, 2014
08:37 EDTIMMUImmunomedics says partial response achieved for 11 months in IMMU-130 trial
Subscribe for More Information
07:25 EDTMRGEMerge Healthcare launches Merge One solution for ambulatory radiology
Subscribe for More Information
07:24 EDTISISGoldman to hold a conference
Subscribe for More Information
06:40 EDTISISIsis Pharmaceuticals price target raised to $62 from $53 at Piper Jaffray
Subscribe for More Information
November 19, 2014
20:07 EDTKNDKindred Healthcare 5M share Secondary priced at $19.75
Subscribe for More Information
07:09 EDTBDSIJefferies to hold a conference
2014 Global London Healthcare Conference is being held in London, England on November 19-20.
November 18, 2014
17:09 EDTIMMUImmunomedics veltuzumab designated for orphan status
Subscribe for More Information
15:48 EDTISISGenzyme, Isis present KYNAMRO data at AHA meeting
Genzyme, a Sanofi (SNY) company, and Isis Pharmaceuticals (ISIS) announced that new two-year data from a phase 3 long-term extension study of KYNAMRO injection was presented at a scientific session at the annual American Heart Association meeting. In the study, a retrospective analysis showed that patients treated with KYNAMRO for a mean of two years had a significant reduction in Major Adverse Cardiovascular Events compared to two years prior to therapy. The rate of MACE in patients treated with KYNAMRO for two years were adjudicated by an independent committee and compared to the rate of MACE in the same patients based on their medical history prior to treatment with KYNAMRO. In this analysis, MACE were identified in 62% of patients during two years prior to KYNAMRO treatment, and 9% of patients during a mean of 24.4 months after initiation of treatment with KYNAMRO.
07:37 EDTDEPO, ARNAStifel to hold a conference
Subscribe for More Information
November 17, 2014
07:48 EDTKNDKindred Healthcare files to sell 5M shares of stock and tangible equity units
Kindred Healthcare announced that it has launched concurrent underwritten public offerings of 5,000,000 shares of Kindred's common stock and 150,000 tangible equity units. Each tangible equity unit has a stated amount of $1,000 and is comprised of a prepaid stock purchase contract and a share of mandatory redeemable preferred stock, each issued by the Company. Citigroup Global Markets Inc. and J.P. Morgan Securities LLC are acting as the joint book-running managers for the concurrent offerings.
07:16 EDTQMilken Institute--Faster Cures to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use